8 completed, 5 unknown, 3 active not recruiting, 2 not yet recruiting. 23 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 23 | Completed 8, Unknown 5, Active not recruiting 3, Not yet recruiting 2, Terminated 2, Withdrawn 2, Recruiting 1 |
| Phase 2 | 3 | Unknown 2, Completed 1 |
Follow IgA Nephropathy: new trials by email Literature Review of IgA Nephropathy trials Research Report on IgA Nephropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN) Sibeprenlimab, Standard of care - IgA Nephropathy | Phase 3 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 24 | 2026-10-30 | 2026-10-15 |
| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN Drug: Atrasentan - Berger Disease, Bergers Disease | Phase 3 | Recruiting | Novartis Pharmaceuticals | 28 | 2026-08-06 | 2026-11-06 |
| A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy BHV-1400, Placebo - IgA Nephropathy | Phase 3 | Not yet recruiting | Biohaven Therapeutics Ltd. | 420 | 2026-06-01 | 2026-06-11 |
| Effect of Finerenone in IgA Nephropathy Finerenone, Placebo - IgA Nephropathy | Phase 3 | Unknown | Zhejiang University | 120 | 2024-10-08 | 2024-08-30 |
| A Study of Zigakibart in Adults With IgA Nephropathy BION-1301, Placebo - IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 383 | 2023-07-06 | 2026-04-01 |
| Atacicept in Subjects With IgA Nephropathy Atacicept, Placebo to match Atacicept - IgA Nephropathy, Berger Disease | Phase 3 | Active not recruiting | Vera Therapeutics, Inc. | 428 | 2023-06-29 | 2026-10-01 |
| Study of Telitacicept in Patients With Refractory IgA Nephropathy Telitacicept - IgA Nephropathy | Phase 2 / Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 40 | 2023-03-01 | 2023-02-24 |
| Steroids Therapy in IgA Nephropathy With Crescents Methylprednisolone - IgA Nephropathy | Phase 3 | Unknown | Sixth Affiliated Hospital, Sun Yat-sen University | 200 | 2021-05-24 | 2021-06-04 |
| Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients Placebo, LNP023 - IgA Nephropathy | Phase 3 | Completed | Novartis Pharmaceuticals | 517 | 2021-01-25 | 2026-11-04 |
| Atrasentan in Patients With IgA Nephropathy Atrasentan, Placebo, Zigakibart - IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 404 | 2020-12-11 | 2026-06-04 |
| Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy OMS721, Vehicle (D5W or saline) - IgA Nephropathy | Phase 3 | Terminated | Omeros Corporation | 360 | 2018-04-05 | 2025-12-09 |
| Treatment of IgA Nephropathy According to Renal Lesions corticotherapy, Renin Angiotensin system (RAS) blockade or Inhibitors of sodium glucose transporter 2 (SGLT2i) - IgA Nephropathy | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 62 | 2018-02-20 | 2025-11-20 |
| Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy Prednisolone, Reh-acteoside - IGA Nephropathy | Phase 2 / Phase 3 | Unknown | Sun Yat-sen University | 75 | 2016-05-01 | 2016-02-02 |
| BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Blisibimod, Placebo - IgA Nephropathy | Phase 3 | Withdrawn | Anthera Pharmaceuticals | 2014-10-01 | 2015-07-30 | |
| Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f. Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH), Mycophenolate mofetil (MMF) - IgA Nephropathy | Phase 3 | Unknown | Second Xiangya Hospital of Central South University | 300 | 2014-06-01 | 2014-07-11 |
| BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration Blisibimod, Placebo - IgA Nephropathy | Phase 2 / Phase 3 | Completed | Anthera Pharmaceuticals | 57 | 2013-06-01 | 2017-09-18 |
| Aliskiren for Immunoglobulin A (IgA) Nephropathy Aliskiren, Placebo - IgA Nephropathy | Phase 3 | Completed | Chinese University of Hong Kong | 22 | 2009-04-01 | 2012-12-04 |
| Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy supportive therapy with: ACE-inhibitor / ARB / Statin, supportive and immunosuppressive therapy - IgA Nephropathy | Phase 3 | Completed | RWTH Aachen University | 148 | 2008-02-01 | 2015-09-22 |
| Paricalcitol for the Treatment of Immunoglobulin A Nephropathy paricalcitol - IgA Nephropathy | Phase 3 | Withdrawn | Chinese University of Hong Kong | 2008-01-01 | 2015-08-03 | |
| Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy Omega-3 fatty acid ethylester90 - IgA Nephropathy | Phase 3 | Completed | Kuhnil Pharmaceutical Co., Ltd. | 152 | 2007-11-01 | 2012-09-27 |
Showing 20 of 23. Sign in to see all of them.
Glomerulonephritis, IGA (23) · Proteinuria (7) · Renal Insufficiency, Chronic (6) · Glomerulonephritis (5) · Kidney Diseases (5) · Urologic Diseases (4) · Nephritis (1) · Renal Insufficiency (1)
Autoimmune Diseases (23) · Female Urogenital Diseases (23) · Female Urogenital Diseases and Pregnancy Complications (23) · Immune System Diseases (23) · Male Urogenital Diseases (23) · Urogenital Diseases (23) · Nephritis (22) · Urologic Diseases (19) · Glomerulonephritis (18) · Kidney Diseases (18) · Pathological Conditions, Signs and Symptoms (10) · Signs and Symptoms (7) · Urination Disorders (7) · Urological Manifestations (7) · Chronic Disease (6)
Methylprednisolone (3) · Mycophenolic Acid (3) · Prednisone (3) · AMG623 peptibody (2) · Atrasentan (2) · Adenosine Triphosphate (1) · Angiotensin-Converting Enzyme Inhibitors (1) · Azathioprine (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Immunosuppression Therapy (1) · Irbesartan (1) · Methylprednisolone Hemisuccinate (1) · Omacor (1) · Palliative Care (1) · Prednisolone (1)
Novartis Pharmaceuticals (4) · Anthera Pharmaceuticals (2) · Chinese University of Hong Kong (2) · Sun Yat-sen University (2) · A. Manzoni Hospital (1) · Assistance Publique - Hôpitaux de Paris (1) · Biohaven Therapeutics Ltd. (1) · Kuhnil Pharmaceutical Co., Ltd. (1) · Omeros Corporation (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · RWTH Aachen University (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Second Xiangya Hospital of Central South University (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · St. Joseph's Hospital and Medical Center, Phoenix (1)
China (9) · South Korea (7) · United States (7) · Germany (6) · Taiwan (6) · France (5) · Spain (5) · United Kingdom (5) · Argentina (4) · Australia (4) · Canada (4) · Czechia (4) · Hong Kong (4) · India (4) · Italy (4)
Anping Xu, MD (1) · Byung-Joo Park, MD,PhD,FISPE (1) · Cheuk Chun Szeto, MD (1) · Eric Michael, MD (1) · Jinli Zhang, MD (1) · Juergen Floege, Prof. Dr. (1) · Junzhou Fu, MD (1) · Khalil El Karoui (1) · Li Hao, MD (1) · Menghua Chen, MD (1) · Qinkai Chen, MD (1) · Ronald J Hogg, M.D. (1)
PMID 38299639, PMID 38864363, PMID 37772889, PMID 26032537, PMID 26630142, PMID 35675911, PMID 10093981, PMID 10676716, PMID 11877568, PMID 14694168, PMID 18587715, PMID 23675422, PMID 23782179, PMID 28341274, PMID 28763548, PMID 37914086, PMID 38059359, PMID 39453772, PMID 39460694, PMID 39462308, PMID 40465397, PMID 40482854, PMID 40627446, PMID 41196369, PMID 41442197, PMID 41620980, PMID 41661687, PMID 41910396, PMID 42205925, PMID 42242268, PMID 42909451
2016 (1)